Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant
Status:
Withdrawn
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to examine the role of an immune modulatory drug (IMID)
in combination with elotuzumab, in a lenalidomide-free approach to maintenance therapy
following second unplanned autologous peripheral blood stem cell transplant (PBSCT) for
relapsed multiple myeloma.